TP53 and B-cell chronic lymphocytic leukemia: A retrospective evaluation of the outcome of FCR-treated CLL patients showed a similar median PFS rate between BIRC3- and TP53-disrupted CLL patients (2.2 and 2.6 years, respectively), significantly inferior to the PFS of BIRC3 wild-type patients [34].